Generics - Diabetes, Oncology

Filter

Current filters:

DiabetesOncology

Popular Filters

Intas Pharma settles with Roche over Xeloda; Merck & Co wins injunction against Aprica

25-06-2013

Indian drugmaker Intas Pharmaceuticals and its wholly owned subsidiary Accord Healthcare have entered…

Aprica PharmaceuticalsAsia-PacificDiabetesGenericsIntas PharmaceuticalsMerck & CoNorth AmericaOncologyPatentsRocheXeloda

Some 40% of G7 ESA markets to be biosimilars by 2020, and insulins to reach $1 billion, says DR report

30-10-2011

By 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40% market share…

BiotechnologyDiabetesGenericsGlobalMarkets & MarketingOncology

Back to top